ArticleGastroenterology research and practice2012
The Optimal First-Line Therapy of Helicobacter pylori Infection in Year 2012.
Article in Gastroenterology research and practice, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Sequential versus concomitant therapy for treatment of Helicobacter pylori infection: an updated systematic review and meta-analysis.European journal of clinical pharmacology · 2018Pooled it
- The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America.The American journal of gastroenterology · 2014Pooled it
- Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection.World journal of gastroenterology · 2015Trial
- Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication.World journal of gastroenterology · 2015Trial
- Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade "A" Success Rate for First-Line Helicobacter pylori Eradication.BioMed research international · 2015Trial
- Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori.World journal of gastroenterology · 2012Trial
- Review
- Variants *1, *2, *3 and *17 of CYP2C19 Cytochrome among Helicobacter Pylori Carriers from Manaus, Amazonas State, Brazil.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Article
- Simvastatin improves the eradication rate ofInfection and drug resistance · 2019Article
- Microarray-Based Detection and Clinical Evaluation forBioMed research international · 2018Article
- Comparing the Efficacy of Concomitant Therapy with Sequential Therapy as the First-Line Therapy of Helicobacter pylori Eradication.Gastroenterology research and practice · 2016Article
- Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective.Molecules (Basel, Switzerland) · 2015Review
- CYP2C19 polymorphism influences Helicobacter pylori eradication.World journal of gastroenterology · 2014Review
- Gastroretentive drug delivery systems for the treatment of Helicobacter pylori.World journal of gastroenterology · 2014Review
- Eradication of Helicobacter pylori infection.The Kaohsiung journal of medical sciences · 2014Review
- Choosing optimal first-line Helicobacter pylori therapy: a view from a region with high rates of antibiotic resistance.Current pharmaceutical design · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper reviews the literature about first-line therapies for H. pylori infection in recent years. First-line therapies are facing a challenge because of increasing treatment failure due to elevated antibiotics resistance. Several new treatment strategies that recently emerged to overcome antibiotic resistance have been surveyed. Alternative first-line therapies include bismuth-containing quadruple therapy, sequential therapy, concomitant therapy, and hybrid therapy. Levofloxacin-based therapy shows impressive efficacy but might be employed as rescue treatment due to rapidly raising resistance. Rifabutin-based therapy is also regarded as a rescue therapy. Several factors including antibiotics resistance, patient compliance, and CYP 2C19 genotypes could influence the outcome. Clinicians should use antibiotics according to local reports. It is recommended that triple therapy should not be used in areas with high clarithromycin resistance or dual clarithromycin and metronidazole resistance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.